Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma (SERIO)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Italian Sarcoma Group
ClinicalTrials.gov Identifier:
NCT01804374
First received: March 1, 2013
Last updated: March 10, 2014
Last verified: March 2014
  Purpose

This is a trial for patients affected by metastatic or relapsed osteosarcoma which progressed after first or further line treatments. In this trial, all patients will be treated until progression or unacceptable toxicity with sorafenib and everolimus. The treatment with sorafenib and everolimus aimed to obtain a 50% rate of patients free from further progression of the disease after 6 months from study entry.


Condition Intervention Phase
Metastatic Osteosarcoma
Relapsed Osteosarcoma
Drug: Sorafenib
Drug: Everolimus
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II, Open Label, Non-randomized Study of Second or Third Line Treatment With the Combination of Sorafenib and Everolimus in Patients Affected by Relapsed and Non-resectable High-grade Osteosarcoma

Resource links provided by NLM:


Further study details as provided by Italian Sarcoma Group:

Primary Outcome Measures:
  • Progression Free Survival rate at 6 months [ Time Frame: 6 months from registration into the study ] [ Designated as safety issue: No ]
    Progression Free Survival rate at 6 months refers to the rate of patients alive and free from progression of the disease at 6 months from registration into the study. Disease will be assessed every 8 weeks up to 2 years until progression or death whichever came first.


Secondary Outcome Measures:
  • progression free survival [ Time Frame: From randomization until progression or death whichever came first up to 2 years ] [ Designated as safety issue: No ]
    Progression Free Survival (PFS) refers to the time from registration into the study to the date of progressive disease or death whichever came first assessed every 8 weeks up to 2 years. In the absence of progression, time will be censored at the date of last tumor assessment or follow-up

  • overall survival [ Time Frame: From randomization until death followed up to 5 years ] [ Designated as safety issue: No ]
    Overall survival (OS) is the time interval between date of registration into study and the date of death. For alive patients, time will be censored at the date of last follow-up.

  • Overall response rate [ Time Frame: From randomization until progression or death whichever came first up to 2 years ] [ Designated as safety issue: No ]
    Overall response rate refers to the rate of patients with complete, partial or minimal responses (defined as shrinkage of target lesions between 10 and 30%) according to RECIST 1.1. Disease will be assessed every 8 weeks up to 2 years.

  • Duration of response [ Time Frame: calculated from date of first assessement of non-progression until progression or death whichever came first up to 2 years ] [ Designated as safety issue: No ]
    Duration of response refers to the time from the date of the first assessement of non-progression to the date of progressive disease or death. Disease will be assessed every 8 weeks up to 2 years until progression or death whichever came first. In the absence of progression time will be censored at the date of last tumor assessment or follow-up.

  • Non-dimensional pattern of response [ Time Frame: calculated from randomization until progression or death whichever came first up to 2 years ] [ Designated as safety issue: No ]

    Non-dimensional pattern of response refers to the evaluation of any consistent variation in radio metabolic diagnostic test (i.e. PET or Bone scan) and/or changes in signal intensity, contrast uptake/enhancement and tumor density at CT/MRI according to Modified Response Criteria (MRC). From this point of view, patients will be considered in response if there has been an objective response or at least ONE of the following criteria are met:

    1. An unequivocal reduction in tumor density at CT scan;
    2. An unequivocal reduction in signal intensity and/or contrast enhancement at MRI;
    3. An unequivocal reduction in SUV at PET scan;
    4. An unequivocal reduction in bone scan uptake.

    Disease will be assessed every 8 weeks up to 2 years until progression or death whichever came first.


  • clinical benefit [ Time Frame: evaluated at each visit from randomizzation until progression or death whichever came first up to 2 years ] [ Designated as safety issue: No ]
    Clinical Benefit will be prospectively evaluated by means of Pain and Analgesic Scale recording of analgesic consume and as lack of progression of disease at six months.

  • Safety [ Time Frame: assessed at each visit from randomizzation until 28 days after the last dose of study treatment assumption up to 2 years ] [ Designated as safety issue: Yes ]
    Safety will be captured by recording: physical examinations, vital signs, performance status/body weight; blood tests and chemistry tests; intensity and severity of adverse events, use of analgesic medication at each visit until 28 days after last dose of study treatment assumption up to 2 years. Adverse events will be evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0


Other Outcome Measures:
  • Expression of MAPKs pathway, VEGFR, PDGFR, Ezrin/Moesin and mTOR pathway (pS6 expression) [ Time Frame: as soon as tissue samples are available or within 2 months from subject study entry ] [ Designated as safety issue: No ]
    Immunohistochemical evaluation of the expression of MAPKs pathway, VEGFR, PDGFR, Ezrin/Moesin and mTOR pathway (pS6 expression)on tissue samples from primary or metastatic tumors.

  • Correlation between oncogenes/metabolic pathways and clinical outcome parameters [ Time Frame: at the time of first survival analysis performed at least 6 months after last subject registration ] [ Designated as safety issue: No ]
    Correlation of both primary and secondary objectives with the expression of the following oncogenes/metabolic pathways: MAPKs, VEGFR, PDGFR, Ezrin/Moesin and mTOR pathway (pS6 expression)

  • Predictive and prognostic role of serum lactate dehydrogenase and serum alkaline phosphatase [ Time Frame: at the time of first survival analysis performed at least 6 months after last subject registration ] [ Designated as safety issue: No ]
    Serum samples for evaluation of levels of lactate dehydrogenase (LDH) and alkaline phosphatase (ALP) will be collected at each visit until progression or death whichever came first up to 2 years.


Estimated Enrollment: 37
Study Start Date: June 2011
Estimated Study Completion Date: July 2014
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: sorafenib and everolimus
This is an open label study: all patients will be treated with sorafenib 400 mg twice a day in combination with everolimus 5mg per day
Drug: Sorafenib
Sorafenib tablet 200 milligrams packed in bottle containing 140 tablets. Sorafenib will be administered orally twice daily at the same time every day. Two 200 mg tablets will be taken either one hour before or two hours after a meal followed by a glass of water in the morning and in the evening. In general, patient should have a low to moderate fat meal. Patients will receive Sorafenib until progression, toxicity, withdrawal of informed consent or clinical investigator decision
Other Names:
  • BAY 43-9006
  • Nexavar
Drug: Everolimus
Everolimus is formulated in tablets of 2.5 or 5 mg strength, blister-packed under aluminum foil in units of 10 tablets. Everolimus will be administered orally once daily at the same time every day immediately after a meal, as a single dose of 5 mg. Patients should have a low-fat breakfast. After this light meal, study medication of Everolimus is to be taken. The tablets of Everolimus should not be chewed or crushed. Patients will receive Everolimus until progression, toxicity, withdrawal of informed consent or clinical investigator decision
Other Names:
  • RAD001
  • Afinitor
  • Certican

Detailed Description:

Patients affected by metastatic or relapsed osteosarcoma which progressed after first or further line treatments still have a poor outcome. Standard chemotherapy has limited activity in these patients.

In a previous study in patient affected by relapsed unresectable osteosarcoma, sorafenib alone demonstrated promising activity. In the preclinical setting, everolimus was able to improve the activity of sorafenib. Sorafenib and everolimus, by hitting crucial pathways which are essential for osteosarcoma cell proliferation and survival, with an entirely different approach aimed to overcome the resistance to standard chemotherapy showed by relapsed osteosarcoma. In this trial, all patients will be treated with sorafenib and everolimus at the dosage of 800 mg and 5 mg per day, respectively. Both drugs have to be taken orally. The treatment will be continued until progression or unacceptable toxicities. The objective of the present trial is to obtain a 50% rate of patients alive and free from progression of their disease 6 months after trial enrolment. The disease will be evaluated every 2 months with a CT scan.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with histologically documented and not surgically resectable or metastatic high-grade osteosarcoma which progressed after first or second line treatments for relapsing disease
  • Measurable disease as defined by RECIST criteria vs. 1.1 (bone lesions are allowed). Baseline evaluations must be completed within 28 days prior to enrollment
  • Eastern Cooperative Oncology Group(ECOG) Performance Status of 0 or 1. ECOG PS 2 patients are eligible if the PS 2 depends solely on orthopedic problems
  • Estimated life expectancy of at least 3months
  • Age≥18 years
  • Adequate bone marrow, liver and renal function: Hemoglobin>9.0g/dl, Absolute neutrophil count>1,500/mm3, Platelet>100,000/μl Total bilirubin<1.5 times the upper limit of normal (ULN), ALT and AST<2.5xULN (<5xULN for patients with liver involvement of their cancer), PT-INR/PTT<1.5xULN, Serum creatinine<2xULN
  • Written informed consent

Exclusion Criteria:

  • Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol
  • Patients with any severe and/or uncontrolled medical conditions such as unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction ≤6months, serious uncontrolled cardiac arrhythmia, uncontrolled hyperlipidemia, active or uncontrolled severe infection, cirrhosis, chronic or persistent active hepatitis or severely impaired lung function.
  • History of HIV infection and active clinically serious infections (>grade 2 according to NCI-CTCAE vs. 4.0)
  • Symptomatic metastatic brain or meningeal tumors (unless the patient is >6months from definitive therapy, has a negative imaging study within 4weeks of study entry and is clinically stable with respect to the tumor at the time of study entry)
  • Patients with seizure disorders requiring medication
  • Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 7days of the start of treatment. Both men and women must use adequate barrier birth control measures during the course of the trial and 8weeks after last dose of study drug
  • Patients with evidence or history of bleeding diathesis
  • Patients undergoing renal dialysis
  • Patients unable to swallow oral medications
  • Uncontrolled diabetes (fasting glucose>2xULN)
  • Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent (except corticosteroids with a daily dosage equivalent to prednisone ≤20mg for adrenal insufficiency). Patients receiving corticosteroids must be on a stable dose for ≥4weeks prior to the first dose of Everolimus. Topical or inhaled corticosteroids are permitted
  • Patients with a history of another malignancy within 5years prior to study entry, except curatively treated non-melanotic skin cancer or in-situ cervical cancer skin or other solid tumors curatively treated with no evidence of disease for ≥3years. Patients with severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol
  • Anticancer chemotherapy or immunotherapy during the study or within 4weeks of study entry
  • Radiotherapy during study or within 3weeks of start of study drug. (Palliative radiotherapy will be allowed)
  • Major surgery within 4weeks of start of study
  • Investigational drug therapy outside of this trial during or within 4weeks of study entry
  • Prior exposure to the study drugs or their analogues
  • Patients with known hypersensitivity to sorafenib, everolimus or other rapamycin analogs, or to its excipients
  • Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
  • A history of noncompliance to medical regimens or inability or unwillingness to return for scheduled visits
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01804374

Locations
Italy
Fondazione del Piemonte per l'Oncologia IRCC Candiolo
Candiolo, Torino, Italy, 10060
Sponsors and Collaborators
Italian Sarcoma Group
Investigators
Principal Investigator: Massimo Aglietta, MD IRCC Candiolo
Study Director: Giovanni Grignani, MD IRCC Candiolo
Study Chair: Piero Picci, MD Italian Sarcoma Group
  More Information

No publications provided

Responsible Party: Italian Sarcoma Group
ClinicalTrials.gov Identifier: NCT01804374     History of Changes
Other Study ID Numbers: SERIO
Study First Received: March 1, 2013
Last Updated: March 10, 2014
Health Authority: Italy: Ministry of Health
Italy: The Italian Medicines Agency

Keywords provided by Italian Sarcoma Group:
osteosarcoma
sorafenib
everolimus
sarcoma

Additional relevant MeSH terms:
Osteosarcoma
Neoplasms, Bone Tissue
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Sarcoma
Everolimus
Sirolimus
Sorafenib
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Antibiotics, Antineoplastic
Antineoplastic Agents
Antifungal Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 19, 2014